Savient Nuflexxa Approval For Knee Arthritis May Aid Sale Of BTG Unit
This article was originally published in The Gray Sheet
Executive Summary
Savient Pharmaceuticals' planned divestiture of its Bio-Technology General unit to fund drug R&D could get a boost from PMA approval of its hyaluronic acid injection for knee osteoarthritis, announced Dec. 7
You may also be interested in...
Osteoarthritis Knee-Treatment Device Firms Clash Over Physician Fees
Genzyme is urging CMS to retain a single HCPCS procedure billing code for the three hyaluronic acid-based devices competing with its Synvisc
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.